SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novavax NVAX
NVAX 8.400-0.4%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Paul Senior who wrote (116)10/26/2021 5:47:11 PM
From: recycled_electron   of 166
 
Covovax - Serum Institute of India's version of US firm Novavax's Covid-19 vaccine candidate - is expected to receive approval from the drug regulator by January, company CEO Adar Poonawalla has said. SII has been submitting trial data to the drug regulator on a rolling basis and the final data will be submitted soon, he told ET. "Covovax should be licensed in December-January," he said.

The drug regulator had earlier asked the company - which had applied for emergency use authorisatio ..

Read more at:
economictimes.indiatimes.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News